FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Wendy Rathmell

Research Profile

Disorders

Chemicals & Drugs

Living Beings

Physiology

Concepts & Ideas

Treatment Outcome

Procedures

Co-author Network

Publications

TOP 3
Paulo A Gameiro; Alexandra Arreola; Rania Baker; Pilar López-Larrubia; Ana M Metelo; Aria Olumi; Rocio Pérez-Carro; Wendy Rathmell; Gregory Stephanopoulos; Zongwei Wang; Juanjuan Yang; Othon Iliopoulos
In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation.
Young E Whang; Andrew J Armstrong; Jeffrey M Crane; Paul A Godley; Gayle Grigson; William Y Kim; Dominic T Moore; Karla Morris; Raj S Pruthi; Wendy Rathmell; Eric M Wallen; Catharine P Watkins; Daniel J George
A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.
Ronald C Chen; Wing-Keung Chiu; Jeffrey M Crane; Paul A Godley; Leroy G Hoffman; William Y Kim; Raj S Pruthi; Wendy Rathmell; Julian G Rosenman; Eric M Wallen; Andrew Z Wang; Young E Whang
Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Wendy Rathmell (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Paulo A Gameiro; Alexandra Arreola; Rania Baker; Pilar López-Larrubia; Ana M Metelo; Aria Olumi; Rocio Pérez-Carro; Wendy Rathmell; Gregory Stephanopoulos; Zongwei Wang; Juanjuan Yang; Othon Iliopoulos
In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation.
Cell metabolism 2013;17(3):372-85.
2013: Young E Whang; Andrew J Armstrong; Jeffrey M Crane; Paul A Godley; Gayle Grigson; William Y Kim; Dominic T Moore; Karla Morris; Raj S Pruthi; Wendy Rathmell; Eric M Wallen; Catharine P Watkins; Daniel J George
A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.
Urologic oncology 2013;31(1):82-6.
2012: Ronald C Chen; Wing-Keung Chiu; Jeffrey M Crane; Paul A Godley; Leroy G Hoffman; William Y Kim; Raj S Pruthi; Wendy Rathmell; Julian G Rosenman; Eric M Wallen; Andrew Z Wang; Young E Whang
Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.
BJU international 2012;110(11 Pt B):E721-6.
2012: Ankur M Manvar; Matthew Nielsen; Norris Nolan; Raj S Pruthi; Wendy Rathmell; Jed Ferguson; Eric M Wallen; Mathew C Raynor
Carcinoma in a cadaveric transplant kidney.
Urology 2012;79(4):758-60.
2011: William Y Kim; Raj S Pruthi; Wendy Rathmell; Julian G Rosenman; Eric M Wallen; Catharine Watkins; Young E Whang; Maria Q Baggstrom; Lav K Goyal; Gayle Grigson; Paul A Godley
Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
Urologic oncology 2011;29(6):608-13.
2011: Brian L Teng; Shufen Chen; Kathryn E Hacker; Anthony R Means; Wendy Rathmell
Tumor suppressive activity of prolyl isomerase Pin1 in renal cell carcinoma.
Molecular oncology 2011;5(5):465-74.
2011: Raj Kurpad; Matthew Nielsen; Ava Pettiford; Wendy Rathmell; Heather Schultz; LuAnn Smith; Eric Wallen; Young E Whang; Julia Fielding; Paul Godley; William Kim; Raj S Pruthi
A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions?
Urologic oncology 2011;29(4):378-82.
2010: A Rose Brannon; Wendy Rathmell
Renal cell carcinoma: where will the state-of-the-art lead us?
Current oncology reports 2010;12(3):193-201.
2010: Wendy Rathmell; Paul A Godley
Recent updates in renal cell carcinoma.
Current opinion in oncology 2010;22(3):250-6.
2010: C Lance Cowey; Julia R Fielding; Wendy Rathmell
The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.
Urology 2010;75(5):1108-13.e1.
2010: C Lance Cowey; Chirag Amin; Raj S Pruthi; Eric Wallen; Matthew Nielsen; Gayle Grigson; Cathy Watkins; Keith V Nance; Jeffrey Crane; Mark Jalkut; Dominic T Moore; William Kim; Paul A Godley; Young E Whang; Julia R Fielding; Wendy Rathmell
Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(9):1502-7.
2010: Shufen Chen; Christie A Sanford; Junjiang Sun; Vivian Choi; Terry Van Dyke; R Jude Samulski; Wendy Rathmell
VHL and PTEN loss coordinate to promote mouse liver vascular lesions.
Angiogenesis 2010;13(1):59-69.
2010: Wendy Rathmell; Raj S Pruthi; Eric Wallen
Neoadjuvant treatment of renal cell carcinoma.
Urologic oncology 2010;28(1):69-73.
2009: T M Wright; A R Brannon; J D Gordan; A J Mikels; C Mitchell; S Chen; I Espinosa; M van de Rijn; Raj S Pruthi; Eric Wallen; Lloyd J Edwards; Roel Nusse; Wendy Rathmell
Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma.
Oncogene 2009;28(27):2513-23.
2009: C M Lee; M M Hickey; C A Sanford; C G McGuire; C L Cowey; M Celeste Simon; Wendy Rathmell
VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.
Oncogene 2009;28(14):1694-705.
2009: C Lance Cowey; Wendy Rathmell
VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.
Current oncology reports 2009;11(2):94-101.
2008: John D Gordan; Priti Lal; Vijay R Dondeti; Richard Letrero; Krishna N Parekh; C Elisa Oquendo; Roger A. Greenberg; Keith T Flaherty; Wendy Rathmell; Brian Keith; M Celeste Simon; Katherine L Nathanson
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.
Cancer cell 2008;14(6):435-46.
2008: Chirag Amin; Eric Wallen; Raj S Pruthi; Benjamin F Calvo; Paul A Godley; Wendy Rathmell
Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy.
Urology 2008;72(4):864-8.
2008: Wendy Rathmell; J Paul Monk
High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review.
Urology 2008;72(3):659-63.
2008: Brian I Rini; Wendy Rathmell; Paul A Godley
Renal cell carcinoma.
Current opinion in oncology 2008;20(3):300-6.
2008: Kathryn E Hacker; Caroline Martz Lee; Wendy Rathmell
VHL type 2B mutations retain VBC complex form and function.
PloS one 2008;3(11):e3801.
2008: Wendy Rathmell; Shufen Chen
VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.
Expert review of anticancer therapy 2008;8(1):63-73.
2007: Michele M Hickey; Jennifer C Lam; Natalie A. Bezman; Wendy Rathmell; M Celeste Simon
von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis.
The Journal of clinical investigation 2007;117(12):3879-89.
2007: Jared A Gollob; Wendy Rathmell; Tina M Richmond; Christine B Marino; Elizabeth K Miller; Gayle Grigson; Catharine Watkins; Lin Gu; Bercedis L Peterson; John J Wright
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(22):3288-95.
2007: Wendy Rathmell; Caroline A Martz; Brian I Rini
Renal cell carcinoma.
Current opinion in oncology 2007;19(3):234-40.
2007: Brian I Rini; Wendy Rathmell
Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 2):741s-746s.
2006: Brian I Rini; Steven C Campbell; Wendy Rathmell
Renal cell carcinoma.
Current opinion in oncology 2006;18(3):289-96.
2005: Wendy Rathmell; Tricia M Wright; Brian I Rini
Molecularly targeted therapy in renal cell carcinoma.
Expert review of anticancer therapy 2005;5(6):1031-40.
2005: Wendy Rathmell; M Celeste Simon
VHL: oxygen sensing and vasculogenesis.
Journal of thrombosis and haemostasis : JTH 2005;3(12):2627-32.
2005: Wendy Rathmell; Paul A Godley; Brian I Rini
Renal cell carcinoma.
Current opinion in oncology 2005;17(3):261-7.
2004: Wendy Rathmell; Michele M Hickey; Natalie A. Bezman; Christie A Chmielecki; Natalie C Carraway; M Celeste Simon
In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
Cancer research 2004;64(23):8595-603.
2004: Wendy Rathmell; Paul A Godley
Renal cell carcinoma.
Current opinion in oncology 2004;16(3):247-52.
2004: Wendy Rathmell; S Bruce Malkowicz; Christopher Holroyde; Will Luginbuhl; David J Vaughn
Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer.
American journal of clinical oncology 2004;27(2):109-12.
2004: Wendy Rathmell; Geza Acs; M Celeste Simon; David J Vaughn
HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma.
Anticancer research 2004;24(1):167-9.
2003: Fiona A Mack; Wendy Rathmell; Andrew M Arsham; James R Gnarra; Brian Keith; M Celeste Simon
Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth.
Cancer cell 2003;3(1):75-88.
1999: Wendy Rathmell; P Arguin; S Chan; A Yu
Yersinia pseudotuberculosis bacteremia and splenic abscess in a patient with non-insulin-dependent diabetes mellitus.
The Western journal of medicine 1999;170(2):110-2.
1998: Vaughn Smider; Wendy Rathmell; G Brown; S Lewis; Gilbert Chu
Failure of hairpin-ended and nicked DNA To activate DNA-dependent protein kinase: implications for V(D)J recombination.
Molecular and cellular biology 1998;18(11):6853-8.
1997: Wendy Rathmell; William K Kaufmann; JC Hurt; LL Byrd; Gilbert Chu
DNA-dependent protein kinase is not required for accumulation of p53 or cell cycle arrest after DNA damage.
Cancer research 1997;57(1):68-74.
1996: a Errami; Vaughn Smider; Wendy Rathmell; DM He; Eric A Hendrickson; Malgorzata Z Zdzienicka; Gilbert Chu
Ku86 defines the genetic defect and restores X-ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants.
Molecular and cellular biology 1996;16(4):1519-26.
1994: Vaughn Smider; Wendy Rathmell; M R Lieber; Gilbert Chu
Restoration of X-ray resistance and V(D)J recombination in mutant cells by Ku cDNA.
Science (New York, N.Y.) 1994;266(5183):288-91.
1994: Wendy Rathmell; Gilbert Chu
Involvement of the Ku autoantigen in the cellular response to DNA double-strand breaks.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(16):7623-7.
1994: Wendy Rathmell; Gilbert Chu
A DNA end-binding factor involved in double-strand break repair and V(D)J recombination.
Molecular and cellular biology 1994;14(7):4741-8.
1992: D J Wiens; Tamara Nowling; D E Fedderson; Wendy Rathmell; B H Franck
Early heart development in the chick embryo: effects of isotretinoin on cell proliferation, alpha-actin synthesis, and development of contractions.
Differentiation; research in biological diversity 1992;51(2):105-12.